SWITCH: A randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO)/sunitinib (SU) versus SU/SO in the treatment of metastatic renal cell cancer (mRCC).

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Journal of Clinical Oncology

• Publication date

  2014-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2014.32.4_SUPPL.393
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• First-line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta-analysis.

  2023cites this paper
• Targeted therapy for metastatic renal cell carcinoma.

  2020cites this paper
• Time on Therapy for at Least Three Months Correlates with Overall Survival in Metastatic Renal Cell Carcinoma

  2019cites this paper
• Cancer Management by Tyrosine Kinase Inhibitors: Efficacy, Limitation, and Future Strategies

  2019cites this paper
• Clinical Trials for Specific Renal Cancer Subtypes—The Time Will Come!

  2017cites this paper
• MODELING OF ORTHOTOPICAL GROWTH OF HUMAN KIDNEY CANCER WITH SUBCUTANEOUS XENOGRAFTS RPOCH1 ON IMMUNODEFICIENT MICE

  2017cites this paper
• Targeted therapy for metastatic renal cell carcinoma

  2017cites this paper
• Tyrosine Kinase Inhibitors: Sorafenib, Sunitinib, Axitinib, and Pazopanib

  2017cites this paper
• Systemic therapy in metastatic renal cell carcinoma

  2016cites this paper
• New advances in genitourinary cancer: evidence gathered in 2014

  2015cites this paper
• Sorafenib treatment of advanced renal cell carcinoma patients in daily practice: the large international PREDICT study.

  2015cites this paper
• Development of chronic myeloid leukaemia in patients treated with anti-VEGF therapies for clear cell renal cell cancer.

  2015cites this paper
• Prognostic factors in renal cell carcinoma patients treated with sorafenib: results from the Czech registry

  2015cites this paper
• Clinical experience with everolimus in the second-line treatment of advanced renal cell carcinoma

  2015cites this paper
• A systematic review of sequencing and combinations of systemic therapy in metastatic renal cancer.

  2015cites this paper
• Optimizing systemic therapy for metastatic renal cell carcinoma beyond the first-line setting.

  2015cites this paper
• Sites of disease as predictors of outcome in metastatic renal cell carcinoma patients treated with first-line sunitinib or sorafenib

  2015cites this paper
• Therapie des unbehandelten lokal fortgeschrittenen oder metastasierten Nierenzellkarzinoms

  2015cites this paper
• A Systematic Review of the Efficacy and Safety Experience Reported for Sorafenib in Advanced Renal Cell Carcinoma (RCC) in the Post-Approval Setting

  2015cites this paper
• Everolimus in metastatic renal cell carcinoma after failure of initial anti–VEGF therapy: final results of a noninterventional study

  2015cites this paper
• Sorafenib: 10 years after the first pivotal trial.

  2015cites this paper
• Patterns of care for metastatic renal cell carcinoma in Australia

  2015cites this paper
• Sequencing Systemic Therapies for Metastatic Kidney Cancer

  2015cites this paper
• Sequenztherapie und neue Therapieoptionen bei metastasiertem Nierenzellkarzinom

  2015cites this paper
• Сорафениб – первый таргетный агент для лечения метастатического рака почки

  2015cites this paper
• Die Systemische Behandlung des metastasierten Nierenzellkarzinoms – Zurück in die Zukunft?

  2015cites this paper
• Nierenzellkarzinom

  2015cites this paper
• [Systemic Treatment of Metastatic Renal Cell Cancer--Back to the Future?].

  2015cites this paper
• Kidney cancer and 2014: is innovation really over?

  2015cites this paper
• Okrągły stół 2013: zalecenia terapeutyczne w leczeniu systemowym rozsianego raka nerkowokomórkowego

  2014cites this paper
• Urologische Onkologie – Bewährtes und Vielversprechendes in der systemischen Therapie

  2014cites this paper
• Современное представление об алгоритме лекарственного лечения и оптимальной последовательности использования таргетных препаратов

  2014cites this paper
• Tivozanib for the treatment of renal cell carcinoma: results and implications of the TIVO-1 trial.

  2014cites this paper
• The use of sunitinib in renal cell carcinoma: where are we now?

  2014cites this paper
• Current management and future perspectives of metastatic renal cell carcinoma

  2014cites this paper
• Highlights from the ASCO Genitourinary Symposium 2014: focus on renal and prostate cancer

  2014influential citation
• What's new in renal cell cancer research? Highlights of GU-ASCO 2014.

  2014cites this paper
• Rationale and Protocol of SOAP: A Phase II Study to Evaluate the Efficacy of Sorafenib as Second-Line Treatment after Pazopanib in Patients with Advanced Renal Cell Carcinoma

  2014cites this paper
• Sunitinib re-challenge in advanced renal-cell carcinoma

  2014influential citation
• Improving outcomes in metastatic clear cell renal cell carcinoma by sequencing therapy.

  2014cites this paper
• Sequential TKIs in advanced renal-cell carcinoma: a long way to Tipperary

  2014cites this paper
• Pharmacotherapy options for advanced renal cell carcinoma

  2014cites this paper
• Advanced renal cell carcinoma in Australia, 2015: What should we do?

  2014cites this paper
• Management of advanced kidney cancer: Canadian Kidney Cancer Forum consensus update.

  2013cites this paper
• International Journal of Nephrology and Renovascular Disease Dovepress Axitinib in the Treatment of Renal Cell Carcinoma: Patient Selection and Perspectives

  year unknowncites this paper